Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Inflammatory Bowel Diseases|March 12, 2010
Expression of the antimicrobial peptide alpha-defensin/cryptdins in intestinal crypts decreases at the initial phase of intestinal inflammation in a model of inflammatory bowel disease, IL-10-deficient miceYuhei Inaba, Toshifumi Ashida, Takahiro Ito, et al.
Cancer Epidemiology|February 5, 2010
Immunoprecipitation of nucleosomal DNA is a novel procedure to improve the sensitivity of serum screening for the p16 hypermethylation associated with colon cancerJun Sakamoto, Mikihiro Fujiya, Kotaro Okamoto, et al.
Inflammatory Bowel Diseases|July 29, 2015
Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical TrialYasuo Suzuki, Toshiyuki Matsui, Hiroaki Ito, et al.
International Journal of Hematology|September 5, 2013
Ex vivo activation of angiogenic property in human peripheral blood-derived monocytes by thrombopoietinToru Kawamoto, Junpei Sasajima, Yoshiaki Sugiyama, et al.
Biochemical and Biophysical Research Communications|May 8, 2007
Denatured human alpha-defensin attenuates the bactericidal activity and the stability against enzymatic digestionHiroki Tanabe, Tokiyoshi Ayabe, Atsuo Maemoto, et al.
Intestinal Research|February 12, 2019
Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II studyToshifumi Hibi, Satoshi Motoya, Toshifumi Ashida, et al.
Intestinal Research|August 19, 2020
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitisTaku Kobayashi, Hiroaki Ito, Toshifumi Ashida, et al.
Crohn'S & Colitis 360|July 2, 2026
Long-term drug persistence and clinical outcomes of ustekinumab in Crohn's disease: a multicenter real-world study from the Hokkaido phoenix cohortTakahiro Ito, Atsuo Maemoto, Nobuhiro Ueno, et al.
Inflammatory Intestinal Diseases|December 25, 2025
Long-Term Outcomes and Prognostic Factors for Vedolizumab-Treated Japanese Patients with Ulcerative ColitisShinya Fukushima, Takehiko Katsurada, Takahiro Ito, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|March 16, 2011
A multicenter study of the efficacy and safety of leukocytapheresis therapy without concomitant systemic steroid treatment in patients with active ulcerative colitisToshifumi Ashida, Yutaka Kohgo, Akihiro Munakata, et al.
Pageof 5